Genfit moves to jump-start enrollment in slow-going phase 2 liver failure trial

Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. The biotech said the changes reflect the comorbidities of people with acute on-chronic liver failure (ACLF) and the logistics of caring for the patients.

Genfit acquired the drug being studied, VS-01, when it paid 40 million Swiss francs ($47 million) to buy Versantis in 2022. The following year, the biotech began enrolling 60 patients for the first targeted study of the liposomal-based candidate.